Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247


Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Chan KK, Magro C, Shoushtari A, Rudin C, Rotemberg V, Rossi A, Lezcano C, Carrino J, Fernandez D, Postow MA, Apollo A, Lacouture ME, Bass AR.

Oncologist. 2019 Oct 15. pii: theoncologist.2019-0508. doi: 10.1634/theoncologist.2019-0508. [Epub ahead of print] Review.


Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial.

Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, Grosse-Perdekamp MT, Dockter T, Tan AD, Beutler A, Loprinzi CL.

Breast. 2019 Sep 19;48:89-97. doi: 10.1016/j.breast.2019.09.011. [Epub ahead of print]


Drugs as a Frequent Cause of Acute Rash in Patients after CD34+-Selected Peripheral Blood Stem Cell Transplantation.

Klager S, Lacouture ME, Hannum M, Devlin SM, Maloy M, Pulitzer M, Jakubowski AA, Markova A.

Biol Blood Marrow Transplant. 2019 Jul 12. pii: S1083-8791(19)30441-0. doi: 10.1016/j.bbmt.2019.07.009. [Epub ahead of print]


Vemurafenib acts as an aryl hydrocarbon receptor antagonist: Implications for inflammatory cutaneous adverse events.

Hawerkamp HC, Kislat A, Gerber PA, Pollet M, Rolfes KM, Soshilov AA, Denison MS, Momin AA, Arold ST, Datsi A, Braun SA, Oláh P, Lacouture ME, Krutmann J, Haarmann-Stemmann T, Homey B, Meller S.

Allergy. 2019 Jul 3. doi: 10.1111/all.13972. [Epub ahead of print]


Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A.

Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28.


A randomized phase 2 trial of the efficacy and safety of a novel topical povidone-iodine formulation for Cancer therapy-associated Paronychia.

Capriotti KD, Anadkat M, Choi J, Kaffenberger B, McLellan B, Barone S, Kukoyi O, Goldfarb S, Lacouture M.

Invest New Drugs. 2019 Jun 26. doi: 10.1007/s10637-019-00825-0. [Epub ahead of print]


Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, Yang CH, Chung WH, Markova A, Lacouture ME.

J Clin Oncol. 2019 Oct 20;37(30):2746-2758. doi: 10.1200/JCO.18.02141. Epub 2019 Jun 19.


Balancing RAF, MEK, and EGFR inhibitor doses to achieve clinical responses and modulate toxicity in BRAF V600E colorectal cancer.

Mondaca S, Lacouture M, Hersch J, Yaeger R.

JCO Precis Oncol. 2018 Aug 14;2018. doi: 10.1200/PO.18.00088. No abstract available.


Efficacy of MEK inhibition in patients with histiocytic neoplasms.

Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM.

Nature. 2019 Mar;567(7749):521-524. doi: 10.1038/s41586-019-1012-y. Epub 2019 Mar 13.


Management of Immunotherapy-Related Toxicities, Version 1.2019.

Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013.


Nonmelanoma Skin Cancer in Childhood and Young Adult Cancer Survivors Previously Treated With Radiotherapy.

Thorsness SL, Freites-Martinez A, Marchetti MA, Navarrete-Dechent C, Lacouture ME, Tonorezos ES.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):237-243. doi: 10.6004/jnccn.2018.7096.


Assessment of Quality of Life and Treatment Outcomes of Patients With Persistent Postchemotherapy Alopecia.

Freites-Martinez A, Chan D, Sibaud V, Shapiro J, Fabbrocini G, Tosti A, Cho J, Goldfarb S, Modi S, Gajria D, Norton L, Paus R, Cigler T, Lacouture ME.

JAMA Dermatol. 2019 Jun 1;155(6):724-728. doi: 10.1001/jamadermatol.2018.5071. Erratum in: JAMA Dermatol. 2019 Apr 10;:.


The effect of scalp cooling on CIA-related quality of life in breast cancer patients: a systematic review.

Marks DH, Okhovat JP, Hagigeorges D, Manatis-Lornell AJ, Isakoff SJ, Lacouture ME, Senna MM.

Breast Cancer Res Treat. 2019 Jun;175(2):267-276. doi: 10.1007/s10549-019-05169-0. Epub 2019 Feb 26. Review.


Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review.

Lacouture ME, Kopsky DJ, Lilker R, Damstra F, van der Linden MHM, Freites-Martinez A, Nagel MPM.

J Am Podiatr Med Assoc. 2018 Nov;108(6):508-516. doi: 10.7547/17-010. Review.


Incidence and risk of developing photosensitivity with targeted anticancer therapies.

Ciccolini KT, Kim J, Chaudhari SP, Lucas AS, Benhuri B, Duran J, Wu S, Lacouture ME.

J Am Acad Dermatol. 2019 Oct;81(4):1009-1011. doi: 10.1016/j.jaad.2019.01.077. Epub 2019 Feb 5. No abstract available.


Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.

Mori S, Hickey A, Dusza SW, Lacouture ME, Markova A.

J Am Acad Dermatol. 2019 Mar;80(3):608-616. doi: 10.1016/j.jaad.2018.10.039. Epub 2018 Oct 26.


Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics.

Phillips GS, Freites-Martinez A, Wu J, Chan D, Fabbrocini G, Hellmann MD, Lacouture ME.

JAMA Dermatol. 2019 Feb 1;155(2):249-251. doi: 10.1001/jamadermatol.2018.4560. No abstract available.


Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Rozner RN, Freites-Martinez A, Shapiro J, Geer EB, Goldfarb S, Lacouture ME.

Breast Cancer Res Treat. 2019 Feb;174(1):15-26. doi: 10.1007/s10549-018-4996-3. Epub 2018 Nov 22. Review.


EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Sanchez-Vega F, Hechtman JF, Castel P, Ku GY, Tuvy Y, Won H, Fong CJ, Bouvier N, Nanjangud GJ, Soong J, Vakiani E, Schattner M, Kelsen DP, Lefkowitz RA, Brown K, Lacouture ME, Capanu M, Mattar M, Qeriqi B, Cecchi F, Tian Y, Hembrough T, Nagy RJ, Lanman RB, Larson SM, Pandit-Taskar N, Schöder H, Iacobuzio-Donahue CA, Ilson DH, Weber WA, Berger MF, de Stanchina E, Taylor BS, Lewis JS, Solit DB, Carrasquillo JA, Scaltriti M, Schultz N, Janjigian YY.

Cancer Discov. 2019 Feb;9(2):199-209. doi: 10.1158/2159-8290.CD-18-0598. Epub 2018 Nov 21.


Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Lacouture M, Sibaud V.

Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39. doi: 10.1007/s40257-018-0384-3. Review.


Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.

Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV.

Clin J Oncol Nurs. 2018 Oct 1;22(5):542-548. doi: 10.1188/18.CJON.542-548. Review.


Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J.

Oncologist. 2019 Mar;24(3):414-420. doi: 10.1634/theoncologist.2018-0184. Epub 2018 Aug 17.


Radiation Dermatitis: A Prevention Protocol for Patients With Breast Cancer.

Lucas AS, Lacouture M, Schneider SM.

Clin J Oncol Nurs. 2018 Aug 1;22(4):429-437. doi: 10.1188/18.CJON.429-437.


Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.


Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.


Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Wu J, Lacouture ME.

Dermatol Clin. 2018 Jul;36(3):315-324. doi: 10.1016/j.det.2018.02.010. Review.


A Randomized Trial of Mometasone Furoate 0.1% to Reduce High-Grade Acute Radiation Dermatitis in Breast Cancer Patients Receiving Postmastectomy Radiation.

Ho AY, Olm-Shipman M, Zhang Z, Siu CT, Wilgucki M, Phung A, Arnold BB, Porinchak M, Lacouture M, McCormick B, Powell SN, Gelblum DY.

Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):325-333. doi: 10.1016/j.ijrobp.2018.02.006. Epub 2018 Feb 14. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):231.


Hair disorders in cancer survivors.

Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez JJ, Rossi AM, Paus R, Lacouture ME.

J Am Acad Dermatol. 2019 May;80(5):1199-1213. doi: 10.1016/j.jaad.2018.03.056. Epub 2018 Apr 14. Review.


Hair disorders in patients with cancer.

Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME.

J Am Acad Dermatol. 2019 May;80(5):1179-1196. doi: 10.1016/j.jaad.2018.03.055. Epub 2018 Apr 14. Review.


Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME.

Oncologist. 2018 Aug;23(8):891-899. doi: 10.1634/theoncologist.2017-0582. Epub 2018 Apr 12. Review.


Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.

Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME.

JAMA Dermatol. 2018 Jun 1;154(6):670-675. doi: 10.1001/jamadermatol.2018.0454.


Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E.

Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004. Epub 2017 Dec 13.


Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Lacouture ME.

Ann Oncol. 2018 Apr 1;29(4):796-798. doi: 10.1093/annonc/mdy084. No abstract available.


Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.


The microbial flora of taxane therapy-associated nail disease in cancer patients.

Virgen CA, Belum VR, Kamboj M, Goldfarb SB, Blinder VS, Gucalp A, Lacouture ME.

J Am Acad Dermatol. 2018 Mar;78(3):607-609. doi: 10.1016/j.jaad.2017.08.038. No abstract available.


SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.


Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients.

Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.

J Am Acad Dermatol. 2018 Jun;78(6):1102-1109. doi: 10.1016/j.jaad.2017.12.031. Epub 2017 Dec 19.


Combination of imiquimod with cryotherapy in the treatment of penile intraepithelial neoplasia.

Shaw KS, Nguyen GH, Lacouture M, Deng L.

JAAD Case Rep. 2017 Nov 6;3(6):546-549. doi: 10.1016/j.jdcr.2017.07.018. eCollection 2017 Nov. No abstract available.


Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M.

Am J Clin Dermatol. 2018 Jun;19(3):363-375. doi: 10.1007/s40257-017-0337-2. Review.


First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.


Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.

Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, Raje NS, Wolf J, Erinjeri JP, Torrisi J, Lacouture M, Elez E, Martínez-Valle F, Durham B, Arcila ME, Ulaner G, Abdel-Wahab O, Pitcher B, Makrutzki M, Riehl T, Baselga J, Hyman DM.

JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.


Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.


A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME.

Support Care Cancer. 2018 Apr;26(4):1169-1179. doi: 10.1007/s00520-017-3938-7. Epub 2017 Nov 7.


Granuloma annulare associated with immune checkpoint inhibitors.

Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e124-e126. doi: 10.1111/jdv.14617. Epub 2017 Oct 27. No abstract available.


Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.

Shah VV, Wikramanayake TC, DelCanto GM, van den Hurk C, Wu S, Lacouture ME, Jimenez JJ.

J Eur Acad Dermatol Venereol. 2018 May;32(5):720-734. doi: 10.1111/jdv.14612. Epub 2017 Nov 24. Review.


Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME.

J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14. Review.


Olmutinib-induced palmoplantar keratoderma.

Chen KL, Cho YT, Yang CW, Sheen YS, Liang CW, Lacouture ME, Chu CY.

Br J Dermatol. 2018 Feb;178(2):e129-e131. doi: 10.1111/bjd.15935. Epub 2017 Dec 18. No abstract available.


Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.


A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME.

J Am Acad Dermatol. 2017 Sep;77(3):577-579. doi: 10.1016/j.jaad.2017.03.039. No abstract available.


Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

Supplemental Content

Loading ...
Support Center